Stock & Company Details
Equillium Inc $EQ
Price:
N/A
N/A
63M
$91M
52 Week High:
N/A
10 Day Average Volume:
N/A
-4.48
50 Day Moving Average:
N/A
52 Week Low:
N/A
30 Day Average Volume:
N/A
N/A
N/A
N/A
30 Day Change:
N/A
3 Month Change:
N/A
Health Technology
EQ technical indicators
Latest Equillium Inc (EQ) indicator readings as of 2026-10-09.
EQ's 14-day RSI is 29.1, in oversold territory. At $1.41 it is trading 32.2% below its 200-day moving average of $2.08, and below its 50-day average of $2.04. Price sits near the lower Bollinger Band ($1.24 to $2.14). ADX reads 30.1, indicating a trending market.
Overview
Equillium Inc is a biotechnology developing therapies to treat autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph 2 ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.
Finance Bot
Ask your questions
Start by typing a question below.
